化学因子 (DARC) 的达菲抗原受体多态性和对 Plasmodium Vivax疟疾的敏感性在苏丹:一个病例对照研究
Samar Ali Osman1, Elshazali Widaa Ali2,3, Elamin Abdelkarim Elamin1
1Department for Parasitology, Faculty of Medical Laboratory Sciences, Al Neelain University, Khartoum, Sudan.
Materia socio-medica
|February 23, 2026
概括
化学因子的达菲抗原受体 (DARC) 基因中的遗传变异与Plasmodium vivax疟疾易感性有关. 这种FYBES等位基因提供了部分抗性,挑战了以前关于Duffy阴性个体的假设.
科学领域:
- 遗传学 是一个遗传学.
- 传染性疾病 传染性疾病
- 疟疾学 疟疾学
背景情况:
- 达菲抗原受体对化学因子 (DARC) 基因多态性对于理解Plasmodium vivax疟疾至关重要.
- 杜菲阴性个体中新出现的P.vivax感染需要对不断演变的易感性模式进行调查.
研究的目的:
- 调查DARC遗传变异与苏丹P.vivax感染易感性之间的联系.
- 为了阐明P.vivax传染模式和与DARC基因型相关的发病率上升.
主要方法:
- 研究包括405名参与者:202名P.vivax疟疾患者和203名健康献血者.
- 从外围血液中提取DNA.
- 使用聚合酶连锁反应序列特定原始剂 (PCR-SSP) 对DARC多态变异的分析.
主要成果:
- 达菲阴性FYBES/FYBES基因型在健康对照组中比P.vivax患者更频繁.
- 在P.vivax患者中,FYB/FYB,FYB/FYA和FYB/FYBES基因型更常见.
- 在P.vivax患者中,FYA/FYA基因型更常见,而FYA/FYBES在对照组中更常见,尽管在统计学上并不显著.
结论:
- 在FYA和FYB等位基因与P. vivax感染易感性之间存在潜在的关联.
- 这种FYBES等位基因似乎赋予了对P.vivax疟疾的部分抵抗力,即使在同卵性Duffy阴性个体中也是如此.
相关概念视频
Single Nucleotide Polymorphisms-SNPs
18.7K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
18.7K
Principles of Pharmacogenetics: Types of Genetic Variants
29
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
29
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
26
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
26


